FindTrial
Sign In

study for the clinician to decide on bone marrow examination

Study of platelet indices and its role in evaluation of thrombocytopenia

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/03/012407
Enrollment
200
Registered
2018-03-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Patient
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All cases of thrombocytopenia with platelet count below 1,50,000/cu mm with or without bone marrow studies. 2. The cases with sufficient clinico-haematological work up with established clinical diagnosis will be included. 3. Only one sample of the single participant will be taken.

Exclusion criteria

Exclusion criteria: 1. Pseudothrombocytopenia 2. Patients who have received blood transfusion or platelet transfusion within 7 days

Design outcomes

Primary

MeasureTime frame
The cases will be broadly classified into two groups on the basis of cause of thrombocytopenia- due to peripheral hyperdestruction(immune thrombocytopenic purpura; infection like malaria, dengue; drug induced, etc.) and hypoproliferative bone marrow (megaloblastic anaemia; leukaemia; aplastic anaemia; myelodysplastic syndrome; myelofibrosis; multiple myeloma; marrow infilteration).Timepoint: 30th April 2018—

Secondary

MeasureTime frame
Research still going onTimepoint: 31st July 2018—

Countries

India

Contacts

Public ContactKhushboo saran

Vydehi Institute of Medical Sciences and Research Centre

dr.jay_prakash@rediffmail.com8084715507

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026